Weekly Cisplatin-Based Chemoradiotherapy Improves RFS and OS, Although Not Statistically Significant, for Patients with Cervical Cancer and Intermediate Pathologic Risk Factors By Ogkologos - September 24, 2025 563 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NRG Oncology/GOG-263/KGOG1008 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR TAT 2021 Honorary Award: A Recognition in Cancer Drug Development to... February 16, 2021 The OncoLife Survivorship Care Plan: An Educational Tool For Survivors That... March 4, 2021 Addition of an EGFR Antibody to Fluorouracil/Folinic Acid Maintenance Therapy in... September 22, 2021 Same Breast Cancer, Same Place, Same Treatment. This Mother and Daughter... May 7, 2021 Load more HOT NEWS Sacituzumab Govitecan Does Not Demonstrate a Statistically Significant OS Improvement in... First treatment approved in England for advanced bile duct cancer COVID-19 Is Decimating Nursing Homes, So GreaterGood Has Donated Masks To... Adding Abiraterone to ADT and Docetaxel Improves Survival in Metastatic Prostate...
